Collectively, while the antiangiogenic activity of IL31 has been demonstrated in vitro and in vivo, it remains to evaluate whether IL31 affects also subsets of endothelial cells, e.g., tumor associated endothelium, therefore explaining its potent antiangiogenic activity in vivo. Here, IL31 is linked to neoplasm.